We read with interest the article by Kelly et al. 1 which emphasizes the importance of the clinical impact of infusion of haemopoietic progenitor cells (HPC)/donor lymphocytes (DLI) potentially contaminated with bacteria. They suggest that infusions of HPC/DLI, contaminated with bacteria do not cause significant clinical sequelae. However, there is no randomized trial that deals with this important topic. The increasing manipulation of HPC for transplantation and immunotherapy in clinical practice highlights the importance of maintaining sterility of the processed products. 2 The sterility of HPC/DLI is of particular relevance because of the implementation of the EU directive 2004/23/EC in April 2006, which specifies good manufacturing practice (GMP), including the processing of haemopoietic progenitor cells-apheresis (HPC-A), haemopoietic progenitor cells-marrow (HPC-M) and DLI in certified clean rooms. [3] [4] [5] [6] [7] Kelly et al. have demonstrated in a retrospective analysis that the contamination rate is 1.0% in over 15 years of activity and that the infusion of contaminated HPC rarely results in unfavourable outcome for the recipient in the autologous or allogeneic setting. They suggest close monitoring and no necessity for pre-emptive antibiotic therapy with infusion of microbial-positive products.
Bacterial contamination occurs predominantly during graft preparation and manipulation or during collection in the allogeneic setting at the time of bone marrow harvest or PBSC apheresis. However, it may also be present before the collection of HPC owing to morbidity of the patient in the autologous setting as patients may be bacteremic at the time of collection. 8 To obtain GMP accreditation, we investigated the impact of possible contamination of HPC products and the clinical outcome in our unit. We retrospectively analysed microbial sampling performed during processing of bone marrow harvests, donor lymphocyte and PBSC preparation from 2001 to 2005.
The overall number of patients and donors studied was 466. There were 224 allogeneic infusions (MUD 40), 211 autologous infusions and 31 donor lymphocyte infusions.
The time points for the microbial cultures were the following: (1) after collection, (2) before start of processing, (3) after processing, but before cryopreservation, (4) at the time of infusion. Before the introduction of GMP, environmental monitoring was limited to settle plates in the safety cabinet and on the laboratory benches. Six hundred and sixty cultures were done for environmental Aspergillus species was found in control plates but not in samples collected from the products and full investigation demonstrated that this was owing to plate contamination. Blood cultures are routinely obtained from the patient's right atrial catheter and peripheral blood at the time of harvest, irrespective of the patient's clinical condition. All of the positive microbiological cultures were found before processing. No additional contamination was found during processing or thawing.
An indistinguishable microorganism with an identical antibiogram was recovered from blood cultures and HPC cultures in 12.7% of cases. In bone marrow harvests, contamination was found in 11 samples collected before further manipulation. After infusion, fever was the only sign experienced by the patients without other clinical sequelae. In cases when microbiological contamination was apparent, Teicoplanin was given as prophylaxis before the infusion. No clinical adverse events associated with bacterial contamination of PBSC or DLI have been identified. There was no difference in the clinical outcome whether antibiotics were administered or not. Fever was more common in recipients of allogeneic stem cells than in recipients of autologous PBSC. There were no lifethreatening conditions or deaths due to infusion of HPC from which microorganisms were recovered. Clinical sequelae in our unit are compiled on an annual basis. Our data confirm the contention that HPC with bacterial contamination rarely, if ever, affects the clinical outcome.
Although our findings confirm the data obtained by others, we wish to emphasise the impact of a GMP requirement for manipulation and processing of HPC and DLI. The standards established by GMP, [3] [4] [5] [6] [7] and necessitated by the implementation of EU directive 2004/23/ EC [5] [6] [7] 10 need more stringent process control and a validated risk assessment analysis before the infusion of a non-sterile product. The principles laid down by GMP require the demonstration of absence of contamination of a processed product to prevent the risk of possible transmission of infection and to ensure the safety of the infusion. The application of these principles of Quality Assurance in stem-cell processing and the reference to the GMP pharmacopoeia could have a large impact on the approach to the production of HPC and DLI for clinical use. According to GMP, the microbial culture conditions need to be extended until 14 days before a final report is issued, and this clearly poses problems in the allogeneic setting, as the HPC will have been infused on the day of collection.
The clinical decision to infuse a contaminated product may take advantage of a risk assessment analysis required by GMP standards. In our opinion, in cases when microbiological contamination is apparent, teicoplanin should be given as prophylaxis before the infusion and antibiotic used should be administered for as short a period as possible.
Studies that compare the rate of contamination of processed autologous and allogeneic HPCs in certified clean room conditions are controversial. 8, 9 Ritter suggests that compared with non-certified rooms, clean room conditions could have a positive impact on the rate of contamination during processing.
Microbial contamination was found at the time of collection and in samples before further manipulation, and in HPC-A collection. In 12.7% of cases, the microorganism was found in blood cultures and HPC cultures. Both data suggest that the contamination occurred before processing and during procurement.
The conclusion is based on the analysis of the process flow of the products processed and on the type of microbial contamination that occurred. A microbiological and environmental training policy that includes basic principles of GMP has been implemented.
We conclude that the introduction of environmental monitoring guidelines and improvement of training in microbial contamination for personnel involved in procurement facilities could reduce the rate of contamination and improve compliance with GMP regulations. 10 However, the length of time and number of procedures following the introduction of GMP is insufficient to compare with the period investigated in this communication. We anticipate that the introduction of GMP will reduce the incidence of microbiological contamination in the future.
The establishment of a risk assessment analysis of the potential clinical impact of the infusion based on retrospective data and implementation of process control to investigate the possible source of contamination should also be part of quality assurance of collection and harvest procedures. 
